ArticlePharmaceutical research2026
Rational Design, Optimization and Bioinformatic Analysis of Anti-PD-L1 Peptide Conjugated Mocetinostat Prodrug Nanoparticles for Predictive Cancer Chemoimmunotherapeutic Efficacy.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to design and optimize anti-PD-L1 peptide-conjugated mocetinostat prodrug nanoparticles (PD-NPs) as a targeted chemoimmunotherapeutic strategy.
methodRationale design and bioinformatic analysis were performed to determine the binding affinity of PD-NPs with targeted proteins through molecular docking and molecular dynamic simulation. PD-NPs were synthesized by self-assembling EDC/NHS coupling reaction, characterized by different spectroscopical techniques. Enzyme-responsive drug release was assessed through in-vitro drug release study in presence and absence of cathepsin B, and quantified by HPLC and UV-visible spectroscopy. In-vitro studies were performed in A549, NCI-H1975 and NCI-H460 cells to assess HDAC activity, PD-1/PD-L1 binding affinity, intracellular cathepsin B levels, and immune activation. In-vivo toxicity study, hemolysis and pharmacokinetic study were performed to evaluate biological safety profile. Biodistribution, and histopathological evaluations were performed in B16-F10-induced lung tumor-bearing mice to assess therapeutic efficacy of PD-NPs.
resultThe optimized zeta potential value was + 23.26 mV and Polydispersity Index (PDI) 0.21, indicating colloidal stability. TEM analysis demonstrated that PD-NPs has uniform spherical morphology. High drug loading efficiency was estimated to be 83.23 ± 2.5% which include 50.49% of anti-PD-L1 peptide and 32.74% of mocetinostat within the PD-NPs. CD spectroscopy, and DNA intercalation assay confirmed cathepsin B-triggered drug release. In-vitro studies demonstrated PD-NPs significantly exhibited HDAC enzymatic inhibition, PD-1/PD-L1 interaction blockade, and immune activation. In-vivo studies represented PD-NPs efficiently improving hemocompatibility, prolonging systemic circulation, enhancing tumor specific accumulation, and restoring typical architecture of lung tissues.
conclusionPD-NPs showed remarkable structural stability, enzyme-responsive activation, and favorable biocompatibility, indicating their potential as a predictive cancer chemoimmunotherapy.
Indexed as
Identifiers
42204129What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.